Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the…


Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use

Originally posted here:
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the...

Related Posts